Ocugen to Present at Biotech Conferences
News related to:Ocugen, Inc · 2 min read
MALVERN, Pa., Sept. 29, 2026 /CourierPR/ -- Ocugen, Inc., a pioneering biotechnology company dedicated to developing gene therapies for blindness diseases, has announced that its executive leadership team will participate in two upcoming investor and industry conferences. These conferences provide valuable platforms for the company to showcase its innovative gene therapy platform and engage with industry experts and investors.
The session will be moderated by Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen. The conference will take place on Thursday, October 1, 2026, at 1:45-2:30 p.m. CEST.
This session will also be moderated by Dr. Shankar Musunuri. The conference will take place on Tuesday, October 6, 2026, at 2:15-3:15 p.m. MST.
The Litigation Reform Act of 1995, which is subject to these upcoming conferences, underscores Ocugen’s commitment to providing innovative solutions for patients suffering from inherited retinal diseases, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. The company’s gene-agnostic approach to modifier gene therapies is designed to address the underlying disease biology by restoring balance across multiple gene networks, offering hope for millions worldwide.
Ocugen, Inc., a biotechnology company focused on developing gene therapies for blindness diseases, is currently advancing programs for these conditions. The company’s leadership team will present at these two upcoming investor and industry conferences, scheduled for October 1, 2026, in Munich, Germany, and October 6, 2026, in Phoenix, Arizona. The presentations will focus on the company’s breakthrough modifier gene therapy platform and its potential to address significant unmet medical needs. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will moderate both panel discussions.
The company’s gene-agnostic approach to modifier gene therapies is designed to address the underlying disease biology by restoring balance across multiple gene networks, offering hope for millions worldwide. The presentations will provide valuable insights into the company’s strategy and progress, as well as its potential to revolutionize the treatment of blindness diseases. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will moderate both panel discussions, ensuring that the audience receives a comprehensive overview of the company’s research and development efforts.